摘要
目的:观察中药封包联合抗结核药物治疗结核性腹膜炎(TBP)的疗效,并探究药物对患者中医证候积分及腹水癌抗原125(CA125)、白细胞介素(IL)-10、可溶性白细胞介素2受体(SIL-2R)水平的影响。方法:随机数表法将陕西省结核病防治院2020年10月—2023年10月就诊的120例TBP患者分为治疗组与对照组,每组60例。对照组接受抗结核药物治疗,治疗组在对照组基础上加用中药封包治疗;1个疗程4周,均干预2个疗程。对比两组中医证候积分变化、疗效及相关症状改善情况,并评价安全性;治疗前、治疗2个疗程后抽血与腹水测定相关指标。结果:治疗组治疗后中医证候积分较治疗前显著下降且低于同时间段对照组(P<0.05),治疗组治疗总有效率93.33%(56/60),高于对照组的80.00%(48/60),差异具有统计学意义(P<0.05)。治疗组患者腹胀、腹痛、发热、腹部包块及腹水消失时间均显著早于对照组(P<0.01)。治疗组治疗后血清腺苷脱氨酶(ADA)、乳酸脱氢酶(LDH)、降钙素原(PCT)水平较治疗前显著下降且低于同时间段对照组(P<0.05)。治疗组治疗后腹水CA125、SIL-2R水平较治疗前显著下降且低于同时间段对照组(P<0.05),IL-10较治疗前显著上升且高于治疗后对照组(P<0.05)。两组不良反应(13.33%vs 8.33%)、并发症(1.67%vs 8.33%)对比差异均无统计学意义(P>0.05)。结论:中药封包联合抗结核药物治疗TBP安全有效,能明显改善患者临床症状,下调腹水CA125、SIL-2R水平,上调IL-10水平。
Objective:To observe the efficacy of traditional Chinese medicine(TCM)external compress combined with anti-tuberculosis drugs in treating tuberculous peritonitis(TBP)and explore its effects on patients'TCM syndrome scores and levels of ascites cancer antigen 125(CA125),interleukin(IL)-10,and soluble interleukin-2 receptor(SIL-2R).Methods:A total of 120 TBP patients treated at Shaanxi Provincial Tuberculosis Control Institute from October 2020 to October 2023 were randomly divided into a treatment group and a control group by random number table method,with 60 cases in each group.The control group received anti-tuberculosis drug treatment,while the treatment group received additional TCM external compress therapy on the basis of the control group.Each treatment course lasted 4 weeks,and both groups were treated for 2 courses.Changes in TCM syndrome scores,efficacy,symptom improvement,and safety were compared between the two groups.Blood and ascites samples were collected before treatment and after 2 courses of treatment to measure relevant indicators.Results:After treatment,the TCM syndrome scores in the treatment group decreased significantly compared to baseline and were lower than those in the control group at the same time point(P<0.05).The total effective rate in the treatment group was 93.33%(56/60),higher than 80.00%(48/60)in the control group,with a statistically significant difference(P<0.05).The disappearance times of abdominal distension,abdominal pain,fever,abdominal mass,and ascites in the treatment group were significantly shorter than those in the control group(P<0.01).After treatment,serum levels of adenosine deaminase(ADA),lactate dehydrogenase(LDH),and procalcitonin(PCT)in the treatment group decreased significantly compared to baseline and were lower than those in the control group at the same time point(P<0.05).The levels of ascites CA125 and SIL-2R in the treatment group decreased significantly compared to baseline and were lower than those in the control group at the same time point(P<0.05),while IL-10 levels increased significantly compared to baseline and were higher than those in the control group after treatment(P<0.05).There were no statistically significant differences in adverse reactions(13.33%vs.8.33%)or complications(1.67%vs.8.33%)between the two groups(P>0.05).Conclusion:TCM external compress combined with anti-tuberculosis drugs is safe and effective for TBP,significantly improving clinical symptoms,reducing ascites CA125 and SIL-2R levels,and increasing IL-10 levels.
作者
邱峥
张燕
景凤英
李彦鹏
南亚
马喜迎
邵小霞
王帆
QIU Zheng;ZHANG Yan;JING Fengying;LI Yanpeng;NAN Ya;MA Xiying;SHAO Xiaoxia;WANG Fan(Department of Integrated Traditional Chinese and Western Medicine,Shaanxi Provincial Tuberculosis Control Institute,Xi'an 710100,China)
出处
《中医药学报》
2025年第5期63-68,共6页
Acta Chinese Medicine and Pharmacology
基金
陕西省中医药管理局项目(SZY-KJCYC-2022-YJ)。
关键词
结核性腹膜炎
中药封包
腹水
癌抗原125
白细胞介素10
可溶性白细胞介素2受体
Tuberculous peritonitis
Traditional Chinese medicine external compress
Ascites
Cancer antigen 125
Interleukin-10
Soluble interleukin-2 receptor
